Evidence map›Paper›PMID 40545292›Full record

ArticleBMJ case reports2025

New-onset dermatomyositis in a patient on nivolumab for metastatic melanoma.

Nina B Curkovic, Douglas B Johnson, Eva Rawlings Parker

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nina B CurkovicDepartment of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Douglas B JohnsonDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Eva Rawlings ParkerDepartment of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA eva.r.parker@vumc.org.ORCID http://orcid.org/0000-0002-2462-5051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of antitranscriptional intermediary factor 1 gamma positive dermatomyositis in a patient with metastatic malignant melanoma undergoing therapy with nivolumab. The patient was diagnosed with dermatomyositis after presenting with severe dysphagia, proximal muscle weakness and typical cutaneous and histologic findings. Nivolumab was discontinued, and intravenous and oral steroids, intravenous immunoglobulin and rituximab were initiated for the treatment of dermatomyositis. Both paraneoplastic dermatomyositis in patients with metastatic melanoma and dermatomyositis presenting as an immune-related adverse event in patients receiving immune checkpoint inhibitors (ICI) are rare. In this case, we highlight features that are consistent with both paraneoplastic dermatomyositis and ICI-induced dermatomyositis.

Indexed as

DermatomyositisImmune Checkpoint InhibitorsMelanomaNivolumabParaneoplastic SyndromesSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansImmunoglobulins, IntravenousRituximabAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsImmunoglobulins, IntravenousNivolumabRituximabConnective tissue diseaseDermatologyParaneoplastic SyndromesSkin cancerUnwanted effects / adverse reactions

Identifiers

PMID40545292
PMCPMC12183785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.